<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28569">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734810</url>
  </required_header>
  <id_info>
    <org_study_id>AN-EPI3332</org_study_id>
    <nct_id>NCT02734810</nct_id>
  </id_info>
  <brief_title>SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis</brief_title>
  <acronym>SIMPLICITY</acronym>
  <official_title>A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anthera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liprotamase consists of 3 soluble, non-porcine digestive enzymes, lipase, protease, and
      amylase, combined in a fixed ratio. Liprotamase is stable in the stomach and can be
      formulated without enteric coating for administration either as a capsule or as a dosing
      solution dissolved in water or juice. The purpose of the present study is to provide
      efficacy and safety data for a new, soluble formulation of liprotamase, Liprotamase Powder
      for Oral Solution, in Cystic Fibrosis patients with exocrine pancreatic insufficiency (EPI).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety in Part A (subjects aged &gt; 7 years), as measured by number of participants with adverse events or laboratory abnormalities</measure>
    <time_frame>1 week</time_frame>
    <description>Descriptive analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coefficient of Fat Absorption (CFA) in Part B (subjects aged 28 days - &lt; 7 years)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Descriptive analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety in Part B (subjects aged 28 days - &lt; 7 years), as measured by number of participants with adverse events or laboratory abnormalities</measure>
    <time_frame>24 weeks</time_frame>
    <description>Descriptive analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms of malabsorption</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth metrics (weight, Height BMI) in Part B (subjects aged 28 days - &lt; 7 years)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Exocrine Pancreatic Insufficiency</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liprotamase Powder for Oral Solution in Subjects aged ≥7 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liprotamase Powder for Oral Solution in Subjects aged 28 days to &lt;7 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liprotamase Powder for Oral Solution</intervention_name>
    <description>Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <other_name>Liprotamase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Part A: males or females ≥7 years of age

          -  For Part B: males or females 28 days to &lt;7 years

          -  Diagnosis of cystic fibrosis based on presentation, genotype and/or sweat chloride

          -  Low fecal elastase

          -  Fair-to-good nutritional status

        Exclusion Criteria:

          -  History or diagnosis of fibrosing colonopathy

          -  Distal intestinal obstruction syndrome in 6 months prior to screening

          -  Receiving enteral tube feedings

          -  Chronic diarrheal illness unrelated to pancreatic insufficiency

          -  Liver abnormalities, or liver or lung transplant, or significant bowel resection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monica Gangal</last_name>
    <email>mgangal@anthera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site 139</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 114</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 117</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 138</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 130</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 110</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 109</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 105</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 122</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 132</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 124</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 135</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 118</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 101</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 136</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 106</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 111</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 116</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 112</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 129</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 21, 2016</lastchanged_date>
  <firstreceived_date>April 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exocrine Pancreatic Insufficiency</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Liprotamase</keyword>
  <keyword>Pancreatic Enzyme Replacement Therapy (PERT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
